NewBridge Pharmaceuticals, a specialty pharmaceutical, biologics, and medical device company serving the Middle East, Africa, Turkey & Caspian regions, today announced that it has entered into an exclusive license and supply agreement with Axcan Pharma for Pylera , an innovative 3-in-1 capsule therapy for the eradication of Helicobacter pylori, a bacterium now recognized as being the main cause of gastric and duodenal ulcers.
The details can be read here.
No comments:
Post a Comment